These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9431363)

  • 21. Sertindole versus haloperidol for schizophrenia.
    Balon R
    Am J Psychiatry; 1998 Sep; 155(9):1303-4. PubMed ID: 9734566
    [No Abstract]   [Full Text] [Related]  

  • 22. Sertindole and impaired atrioventricular function, in the absence of Q-T prolongation: a case report.
    Rizos EN; Leftheriotis D; Douzenis A; Chatziioannou S; Siafakas N; Nika S; Kremastinos D; Lykouras L
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):442. PubMed ID: 20653911
    [No Abstract]   [Full Text] [Related]  

  • 23. [The experience of using the atypical antipsychotic sertindole in psychiatric inpatient clinics in Russia].
    Ivanets NN; Kinkul'kina MA; Avdeeva TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(6):37-41. PubMed ID: 21716249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction to sertindole in clinical practice.
    Peuskens J
    CNS Drugs; 2004; 18 Suppl 2():1-4. PubMed ID: 15461311
    [No Abstract]   [Full Text] [Related]  

  • 25. Sertindole hydrochloride: a novel antipsychotic medication with a favorable side effect profile.
    Brown GR; Radford JM
    South Med J; 1997 Jul; 90(7):691-3. PubMed ID: 9225889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology.
    Peuskens J; Tanghøj P; Mittoux A;
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):425-33. PubMed ID: 18384186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Practical aspects of drug resistance in schizophrenia].
    Jarema M; Kucińska M
    Psychiatr Pol; 2000; 34(5):721-40. PubMed ID: 11202015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Zetidoline in the treatment of schizophrenia--initial experiences].
    Molcan J; Korínková V; Koníková M; Rakús A; Pribyl R
    Cesk Psychiatr; 1984 Jun; 80(3):143-5. PubMed ID: 6148151
    [No Abstract]   [Full Text] [Related]  

  • 29. Perospirone in the treatment of schizophrenia: effect on verbal memory organization.
    Araki T; Yamasue H; Sumiyoshi T; Kuwabara H; Suga M; Iwanami A; Kato N; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):204-8. PubMed ID: 16300872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phases of the menstrual cycle and therapeutic response to neuroleptic therapy in patients with schizophrenia].
    Vanurová I; Yamamotová A
    Cas Lek Cesk; 2001 Oct; 140(21):668-70. PubMed ID: 11766456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Loss of consciousness during treatment with sertindole].
    Haberfellner EM
    Psychiatr Prax; 1999 May; 26(3):150. PubMed ID: 10412716
    [No Abstract]   [Full Text] [Related]  

  • 33. [Perospirone therapy in elderly patients with schizophrenia].
    Masui T; Honma H; Kondo C; Osawa T; Iwasaki S; Matsubara S
    Seishin Shinkeigaku Zasshi; 2003; 105(10):1247-53. PubMed ID: 14679781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term medication in schizophrenic psychoses].
    Gaebel W
    Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S26-31. PubMed ID: 10907610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sertindole causes distinct electrocardiographic T-wave morphology changes.
    Nielsen J; Graff C; Hardahl T; Andersen MP; Kristoffersen J; Struijk JJ; Toft E; Meyer JM
    Eur Neuropsychopharmacol; 2009 Oct; 19(10):702-7. PubMed ID: 19457646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological profile of the atypical neuroleptic sertindole.
    Hyttel J; Arnt J; Costall B; Domeney A; Dragsted N; Lembøl HL; Meier E; Naylor RJ; Nowak G; Sánchez C
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():267A-268A. PubMed ID: 1354033
    [No Abstract]   [Full Text] [Related]  

  • 38. Neuroleptic concentrations in schizophrenic patients: measurements by radioreceptor assay and gas chromatography.
    Javaid JI; Davis JM; Dysken MW; Janicak P; Casper R
    Psychopharmacol Bull; 1983; 19(1):72-4. PubMed ID: 6131469
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of delusional parasitosis with sertindole.
    Yorston G
    Int J Geriatr Psychiatry; 1997 Nov; 12(11):1127-8. PubMed ID: 9427097
    [No Abstract]   [Full Text] [Related]  

  • 40. Ondansetron in treatment of schizophrenia.
    White A; Corn TH; Feetham C; Faulconbridge C
    Lancet; 1991 May; 337(8750):1173. PubMed ID: 1674058
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.